The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria

Summary

Sickle Cell Anemia (SCA) occurs in 300,000 newborns per year in the world, with 150,000 affected births in Nigeria, alone. With improvement in survival for children with SCA in both high- and low-resource countries, neurological morbidity is an emerging significant public health challenge, particularly in countries with a high rate of sickle cell disease (SCD). Both silent cerebral infarcts (SCI) and overt strokes result in significant neurological morbidity and premature death. Five NIH-funded randomized controlled trials (RCT) demonstrated that regular blood transfusion or hydroxyurea therapy are efficacious treatments for primary and secondary stroke prevention in children with SCA. Despite the observation that at least 99% of children with SCA in high-resource settings reach adulthood, and approximately 60% of adults will experience one or more strokes (\~50% with SCI and \~10% with overt strokes) and the high disease-burden in Nigeria, the prevalence and incidence rates of new and recurrent stroke (overt and silent strokes)have not been collected systematically in children and young adults (16-25 years old) with SCA. In the last decade, there has been growing use of stroke registries in economically advanced nations, particularly for epidemiological purposes of trend analysis, clinical effectiveness, compliance to guidelines, assessment of implementation, adoption of novel techniques, and quality improvement process. For the first time in clinical centers in Nigeria, the Investigators will conduct an observational epidemiological study to document the prevalence and track the incidence of new and recurrent strokes in children and young adults with SCD. The Investigators will create a stroke registry referred to as the Afolabi Stroke Registry for Children and Young Adults with Sickle Cell Disease in Nigeria. The overall purpose of the stroke registry is to document the natural history of SCD in a low-resource setting and to improve the quality of the care of children and young adults with SCD living in Nigeria.

Conditions

• Sickle Cell Disease
• Stroke
• Neurologic Manifestations
• Neurological Morbidity
• Sickle Cell Anemia in Children
• Sickle Cell Anemia

Interventions

OTHER

This study does not entail offering any intervention; all data collected will be based on standard of care.

This study does not entail offering any intervention; all data collected will be based on standard of care.

Sponsors & Collaborators

• Aminu Kano Teaching Hospital

  collaborator OTHER

• Murtala Muhammed Specialist Hospital

  collaborator OTHER

• Bayero University Kano, Nigeria

  collaborator OTHER

• Vanderbilt University Medical Center

  lead OTHER

Principal Investigators

• Michael R DeBaun, MD, MPH · Vanderbilt University Medical Center

Eligibility

Min Age

5 Years

Max Age

26 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-04-01

Primary Completion

2023-12-31

Completion

2023-12-31

Countries

• United States
• Nigeria

Study Locations